• Je něco špatně v tomto záznamu ?

The importance of serum osteopontin and stanniocalcin-1 in renal cell carcinoma

R. Sobotka, O. Capoun, T. Hanus, T. Zima, M. Kalousova, V. Soukup

. 2018 ; 65 (6) : 958-964.

Jazyk angličtina Země Slovensko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19005395

A total of 56 RCC patients with staging ≥ pT1b were enrolled in a prospective study to assess the prognostic importance of serum levels of osteopontin (OP), stanniocalcin-1 (SC), FGF-23, alpha Klotho and 25-OH-D at the time of diagnosis in renal cell carcinoma (RCC) patients. The relationship between the serum level of the analyzed parameters and recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) was examined, and our control group consisted of 20 patients without cancer. The levels of osteopontin, stanniocalcin-1, FGF-23 and alpha Klotho were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and 25-OH-D by chemiluminiscence immunoanalysis (CLIA). The follow-up period median was 46 months. Renal cell carcinoma recurred in 9 patients and 20 patients died during follow-up; 12 of them from RCC. The level of osteopontin and stanniocalcin-1 varied between the control group and RCC patients (at p=0.02 and p=0.0003). Higher levels of stanniocalcin-1 were detected in the metastatic RCC group than in the localized RCC group (p=0.003). Only the stanniocalcin-1 level at the time of surgery was associated with RFS (p=0.0004). Both OS and CCS were associated with the osteopontin, stanniocalcin-1 and FGF preoperative level. Patients with stanniocalcin-1 level over 1,277 pg/ml and osteopontin level over 100 ng/ml had 17.8 times higher and 7.9 times higher risk of dying from RCC progression, respectively (p<0.001 and p=0.002). High levels of osteopontin, stanniocalcin-1 and FGF 23 at the time of surgery are important prognostic factors related to CSS and OS. Patients with high stanniocalcin-1 level were at risk of tumor recurrence.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc19005395
003      
CZ-PrNML
005      
20191014141755.0
007      
ta
008      
190205s2018 xo d f 000 0|eng||
009      
AR
024    0_
$a 10.4149/neo_2018_171123N759 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xo
100    1_
$a Sobotka, Roman, $d 1979- $7 xx0131095 $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
245    14
$a The importance of serum osteopontin and stanniocalcin-1 in renal cell carcinoma / $c R. Sobotka, O. Capoun, T. Hanus, T. Zima, M. Kalousova, V. Soukup
504    __
$a Literatura
520    9_
$a A total of 56 RCC patients with staging ≥ pT1b were enrolled in a prospective study to assess the prognostic importance of serum levels of osteopontin (OP), stanniocalcin-1 (SC), FGF-23, alpha Klotho and 25-OH-D at the time of diagnosis in renal cell carcinoma (RCC) patients. The relationship between the serum level of the analyzed parameters and recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) was examined, and our control group consisted of 20 patients without cancer. The levels of osteopontin, stanniocalcin-1, FGF-23 and alpha Klotho were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and 25-OH-D by chemiluminiscence immunoanalysis (CLIA). The follow-up period median was 46 months. Renal cell carcinoma recurred in 9 patients and 20 patients died during follow-up; 12 of them from RCC. The level of osteopontin and stanniocalcin-1 varied between the control group and RCC patients (at p=0.02 and p=0.0003). Higher levels of stanniocalcin-1 were detected in the metastatic RCC group than in the localized RCC group (p=0.003). Only the stanniocalcin-1 level at the time of surgery was associated with RFS (p=0.0004). Both OS and CCS were associated with the osteopontin, stanniocalcin-1 and FGF preoperative level. Patients with stanniocalcin-1 level over 1,277 pg/ml and osteopontin level over 100 ng/ml had 17.8 times higher and 7.9 times higher risk of dying from RCC progression, respectively (p<0.001 and p=0.002). High levels of osteopontin, stanniocalcin-1 and FGF 23 at the time of surgery are important prognostic factors related to CSS and OS. Patients with high stanniocalcin-1 level were at risk of tumor recurrence.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    12
$a karcinom z renálních buněk $x diagnóza $7 D002292
650    12
$a nádorové biomarkery $7 D014408
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a osteopontin $x analýza $x krev $7 D053495
650    _2
$a parathormon $x analýza $x krev $7 D010281
650    _2
$a klinická studie jako téma $7 D000068456
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a analýza přežití $7 D016019
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čapoun, Otakar, $d 1981- $7 xx0131076 $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hanuš, Tomáš, $d 1951- $7 nlk19990073190 $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zima, Tomáš, $d 1966- $7 jn20000620440 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kalousová, Marta, $d 1974- $7 mzk2005318016 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Soukup, Viktor, $d 1974- $7 xx0081956 $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$t Neoplasma $x 0028-2685 $g Roč. 65, č. 6 (2018), s. 958-964 $w MED00003470
910    __
$a ABA008 $b A 1194 $c 659 $y 4 $z 0
990    __
$a 20190205091035 $b ABA008
991    __
$a 20191014142220 $b ABA008
999    __
$a ok $b bmc $g 1374018 $s 1043600
BAS    __
$a 3
BMC    __
$a 2018 $b 65 $c 6 $d 958-964 $i 0028-2685 $m Neoplasma $x MED00003470
LZP    __
$c NLK109 $d 20190313 $a NLK 2019-10/pk

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...